| 000 | 01743 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515120956.0 | ||
| 264 | 0 | _c20080527 | |
| 008 | 200805s 0 0 eng d | ||
| 022 | _a1527-7755 | ||
| 024 | 7 |
_a10.1200/JCO.2007.15.2280 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWheatley-Price, Paul | |
| 245 | 0 | 0 |
_aErlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. _h[electronic resource] |
| 260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMay 2008 |
||
| 300 |
_a2350-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 |
_aQuinazolines _xadverse effects |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aDing, Keyue | |
| 700 | 1 | _aSeymour, Lesley | |
| 700 | 1 | _aClark, Gary M | |
| 700 | 1 | _aShepherd, Frances A | |
| 773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 26 _gno. 14 _gp. 2350-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.2007.15.2280 _zAvailable from publisher's website |
| 999 |
_c17962986 _d17962986 |
||